Imprimis Pharmaceuticals Inc. Announces Shift in Strategic Direction

Leveraging its relationships with physicians and pharmacists, Imprimis plans to focus on drug commercialization in four therapeutic areas: Ophthalmology, Wound Management, Urology and Pain

SAN DIEGO, Nov. 6, 2013 — Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company focused on commercializing novel drug formulations invented by physicians and pharmacists through their clinical experience with patients, today announced a shift in the focus of its strategic direction, aimed at diversifying its development and commercialization activities and shortening time to market.
Read more here.